Arcutis to Present at the Guggenheim SMID Cap Biotech Conference
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company will engage in a fireside chat scheduled for Thursday, February 6, 2025, at 1:00 pm ET.
The event, taking place from February 5-6, 2025, will be accessible to viewers through a webcast available in the 'Events' section of Arcutis's website. The webcast recording will remain available for 180 days after the conference concludes.
Arcutis Biotherapeutics (Nasdaq: ARQT), un'azienda biofarmaceutica in fase commerciale specializzata in innovazioni nell'immuno-dermatologia, ha annunciato la sua prossima partecipazione alla Guggenheim SMID Cap Biotech Conference. L'azienda prenderà parte a un colloquio informale programmato per giovedì 6 febbraio 2025, alle 13:00 ET.
L'evento, che si svolgerà dal 5 al 6 febbraio 2025, sarà accessibile agli spettatori tramite un webcast disponibile nella sezione 'Eventi' del sito web di Arcutis. La registrazione del webcast rimarrà disponibile per 180 giorni dopo la conclusione della conferenza.
Arcutis Biotherapeutics (Nasdaq: ARQT), una empresa biofarmacéutica en etapa comercial especializada en innovaciones en inmuno-dermatología, ha anunciado su próxima participación en la Guggenheim SMID Cap Biotech Conference. La compañía participará en una charla informal programada para el jueves 6 de febrero de 2025, a la 1:00 pm ET.
El evento, que tendrá lugar del 5 al 6 de febrero de 2025, estará disponible para los espectadores a través de un webcast que se podrá encontrar en la sección 'Eventos' del sitio web de Arcutis. La grabación del webcast continuará disponible durante 180 días después de la conclusión de la conferencia.
Arcutis Biotherapeutics (Nasdaq: ARQT), 면역 피부과 혁신에 특화된 상업 단계의 생명공학 회사가 구겐하임 SMID 캡 생명공학 회의에 참여할 예정이라고 발표했습니다. 회사는 2025년 2월 6일 목요일 오후 1시 ET에 예정된 화상 대화에 참여할 것입니다.
이 행사는 2025년 2월 5일부터 6일까지 진행되며, 아르쿠티스 웹사이트의 '이벤트' 섹션에서 웹캐스트를 통해 시청할 수 있습니다. 웹캐스트 녹화는 회의 종료 후 180일 동안 제공됩니다.
Arcutis Biotherapeutics (Nasdaq: ARQT), une entreprise biopharmaceutique en phase commerciale spécialisée dans les innovations en immuno-dermatologie, a annoncé sa prochaine participation à la Guggenheim SMID Cap Biotech Conference. L'entreprise participera à une discussion informelle prévue pour jeudi 6 février 2025, à 13h00 ET.
L'événement, qui se déroulera du 5 au 6 février 2025, sera accessible aux spectateurs via un webcast disponible dans la section 'Événements' du site web d'Arcutis. L'enregistrement du webcast sera disponible pendant 180 jours après la fin de la conférence.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das auf Innovationen in der Immunodermatologie spezialisiert ist, hat seine bevorstehende Teilnahme an der Guggenheim SMID Cap Biotech Conference bekannt gegeben. Das Unternehmen wird an einem informellen Gespräch teilnehmen, das für Donnerstag, den 6. Februar 2025, um 13:00 Uhr ET geplant ist.
Die Veranstaltung findet vom 5. bis 6. Februar 2025 statt und wird über ein Webcast für Zuschauer zugänglich sein, der im Bereich 'Veranstaltungen' auf der Website von Arcutis zu finden ist. Die Aufzeichnung des Webcasts bleibt 180 Tage nach dem Ende der Konferenz verfügbar.
- None.
- None.
WESTLAKE VILLAGE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Guggenheim SMID Cap Biotech Conference, taking place February 5-6, 2025.
Details for the company’s participation are as follows:
Fireside Chat Date: Thursday, February 6, 2025
Fireside Chat Time: 1:00 pm ET
The webcast for this conference may be accessed at the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit http://www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release and the anticipated fireside chat discussion contain “forward-looking” statements, including, among others, statements regarding Arcutis’ potential to address urgent needs and expectations with regard to the timing of data and regulatory events. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Corporate Controller
ir@arcutis.com
FAQ
When is Arcutis (ARQT) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How long will the ARQT Guggenheim Conference webcast be available for viewing?
Where can investors watch Arcutis's (ARQT) Guggenheim Conference presentation?
What type of presentation will ARQT deliver at the February 2025 Guggenheim Conference?
